Inovio Pharma (INOV)'s HIV vaccine

• Announces that its HIV vaccine, PENNVAX-GP, 'produced amongst the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine'

** charts after announcement **

 

Inovio Pharma announces that its HIV vaccine, PENNVAX-GP, 'produced amongst the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine' :
 ....announced that its HIV vaccine, PENNVAX-GP, produced amongst the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine. The vaccine candidate, PENNVAX-GP, consists of a combination of four HIV antigens designed to cover multiple global HIV strains and generate both an antibody (humoral) immune response as well as a T cell (cellular) immune response to both potentially prevent and treat HIV. These preliminary results are from a study supported by the HIV Vaccine Trials Network (:HVTN) and the National Institute of Allergy and Infectious Diseases (:NIAID), part of the National Institutes of Health (:NIH) in collaboration with Inovio.

** charts before announcement **